Shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) have been given an average recommendation of “Hold” by the twelve analysts that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $13.18.
A number of research firms recently weighed in on DBVT. Goldman Sachs Group raised shares of Solaredge Technologies from a “sell” rating to a “neutral” rating and raised their price target for the company from $35.00 to $52.00 in a report on Monday, June 17th. Zacks Investment Research raised shares of HB Fuller from a “sell” rating to a “hold” rating in a report on Wednesday, July 3rd. Finally, BidaskClub raised shares of Zebra Technologies from a “hold” rating to a “buy” rating in a report on Saturday, July 6th.
A number of hedge funds and other institutional investors have recently bought and sold shares of DBVT. Quantamental Technologies LLC boosted its stake in DBV TECHNOLOGIE/S by 63.9% during the 1st quarter. Quantamental Technologies LLC now owns 4,917 shares of the company’s stock valued at $38,000 after acquiring an additional 1,917 shares during the last quarter. Bank of Montreal Can bought a new position in DBV TECHNOLOGIE/S during the 1st quarter valued at $113,000. Norges Bank bought a new position in DBV TECHNOLOGIE/S during the 4th quarter valued at $321,000. OLD Mission Capital LLC boosted its stake in DBV TECHNOLOGIE/S by 1,278.6% during the 4th quarter. OLD Mission Capital LLC now owns 143,338 shares of the company’s stock valued at $920,000 after acquiring an additional 132,941 shares during the last quarter. Finally, Premier Asset Management LLC bought a new position in DBV TECHNOLOGIE/S during the 4th quarter valued at $1,121,000. Hedge funds and other institutional investors own 46.56% of the company’s stock.
About DBV TECHNOLOGIE/S
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
See Also: What is a resistance level?
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.